NASDAQ:ENSC Ensysce Biosciences (ENSC) Stock Price, News & Analysis $0.40 0.00 (-1.20%) Closing price 04:00 PM EasternExtended Trading$0.40 0.00 (0.00%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Ensysce Biosciences Stock (NASDAQ:ENSC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Ensysce Biosciences alerts:Sign Up Key Stats Today's Range$0.39▼$0.4350-Day Range$0.25▼$0.5252-Week Range$0.23▼$2.75Volume173,172 shsAverage Volume7.51 million shsMarket Capitalization$7.69 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Ensysce Biosciences, Inc. is a clinical-stage biotechnology company developing prescription medicines designed to improve the safety of opioid pain treatment. The company focuses on technologies intended to reduce the potential for opioid abuse, misuse, and overdose while preserving analgesic activity. Ensysce’s lead program is PF614, an investigational extended-release oxycodone prodrug being developed with its Trypsin-Activated Abuse Protection (TAAP) technology. The platform is designed to limit the release of active oxycodone when the product is manipulated for non-oral use. Ensysce has also been developing PF614-MPAR, a combination product intended to pair PF614 with an overdose-protection component. The company’s pipeline is aimed primarily at the prescription pain-management market and reflects its broader focus on creating abuse-deterrent and overdose-resistant opioid formulations. Ensysce Biosciences is headquartered in San Diego, California, and its programs remain subject to clinical development and regulatory review.AI Generated. May Contain Errors. Read More Ensysce Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks22nd Percentile Overall ScoreENSC MarketRank™: Ensysce Biosciences scored higher than 22% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingEnsysce Biosciences has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageEnsysce Biosciences has only been the subject of 1 research reports in the past 90 days.Read more about Ensysce Biosciences' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Ensysce Biosciences are expected to grow in the coming year, from ($1.09) to ($0.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ensysce Biosciences is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ensysce Biosciences is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnsysce Biosciences has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Ensysce Biosciences' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.38% of the float of Ensysce Biosciences has been sold short.Short Interest Ratio / Days to CoverEnsysce Biosciences has a short interest ratio ("days to cover") of 1.75, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ensysce Biosciences has recently decreased by 15.49%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEnsysce Biosciences does not currently pay a dividend.Dividend GrowthEnsysce Biosciences does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Ensysce Biosciences this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for ENSC on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days. Company Ownership3.0 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $196,000.00 in company stock, which represents 2.5499% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Ensysce Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $196,000.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders2.80% of the stock of Ensysce Biosciences is held by insiders.Percentage Held by Institutions5.63% of the stock of Ensysce Biosciences is held by institutions.Read more about Ensysce Biosciences' insider trading history. Receive ENSC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ensysce Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ENSC Stock News HeadlinesReviewing Ensysce Biosciences (NASDAQ:ENSC) and Hypermarcas (OTCMKTS:HYPMY)September 29 at 6:14 AM | americanbankingnews.comEnsysce Biosciences Corporate Event Calendar | NASDAQ:ENSCSeptember 9, 2026 | benzinga.comThey're not buying gold. They're buying this.Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, and Millennium by 122%. Kopernik Global made it their largest holding, owning roughly 8% of the company. It holds rights to an 88 million ounce deposit with existing roads, power, and permits that never expire. Market cap sits near $4 billion against a deposit worth hundreds of billions at current gold prices.October 2 at 1:00 AM | Behind the Markets (Ad)Ensysce Biosciences, Inc. (ENSC) Discusses Acquisition of Cy Biopharma and Private Placement Financing Prepared Remarks TranscriptAugust 18, 2026 | seekingalpha.comENSC sets itself up nicely for critical stageAugust 14, 2026 | msn.comEnsysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing - The Globe and MailAugust 7, 2026 | theglobeandmail.comENSC Makes Bold Move that Bolsters Pipeline and FinancesAugust 6, 2026 | msn.comEnsysce Biosciences completes Cy Biopharma acquisition and secures up to $77 million private financingAugust 6, 2026 | msn.comSee More Headlines ENSC Stock Analysis - Frequently Asked Questions How have ENSC shares performed this year? Ensysce Biosciences' stock was trading at $0.92 on January 1st, 2026. Since then, ENSC shares have decreased by 57.1% and is now trading at $0.3950. How were Ensysce Biosciences' earnings last quarter? Ensysce Biosciences, Inc. (NASDAQ:ENSC) issued its quarterly earnings results on Thursday, August, 13th. The company reported ($0.20) EPS for the quarter, hitting analysts' consensus estimates of ($0.20). The firm had revenue of $1.16 million for the quarter, compared to the consensus estimate of $1.20 million. Ensysce Biosciences had a negative net margin of 280.53% and a negative trailing twelve-month return on equity of 2,550.30%. When did Ensysce Biosciences' stock split? Ensysce Biosciences shares reverse split before market open on Friday, March 31st 2023.The 1-12 reverse split was announced on Friday, March 31st 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, March 31st 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. How do I buy shares of Ensysce Biosciences? Shares of ENSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ensysce Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ensysce Biosciences investors own include Predictive Oncology (POAI), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT), Meta Platforms (META), Insulet (PODD) and Broadcom (AVGO). Company Calendar Last Earnings8/13/2026Today10/02/2026Next Earnings (Estimated)11/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ENSC's financial health is in the Green zone, according to TradeSmith. ENSC has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ENSC CIK1716947 Webensysce.com Phone858-263-4196FaxN/AEmployees10Year FoundedN/AProfitability EPS (Trailing Twelve Months)($2.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$10.18 million Net Margins-280.53% Pretax Margin-280.51% Return on Equity-2,550.30% Return on Assets-320.49% Debt Debt-to-Equity RatioN/A Current Ratio0.70 Quick Ratio0.70 Sales & Book Value Annual Sales$5.07 million Price / Sales1.52 Cash FlowN/A Price / Cash FlowN/A Book Value$0.63 per share Price / Book0.63Miscellaneous Outstanding Shares19,460,000Free Float18,912,000Market Cap$7.69 million OptionableNot Optionable Beta1.00 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:ENSC) was last updated on 10/2/2026 by MarketBeat.com Staff. From Our PartnersElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on December 8th. Altuche...Paradigm Press | SponsoredThey're not buying gold. They're buying this.Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...Behind the Markets | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredHow Elon’s Empire Ends (and how to profit)Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...Chaikin Analytics | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ensysce Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ensysce Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
